{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,6,16]],"date-time":"2026-06-16T05:37:19Z","timestamp":1781588239635,"version":"3.54.5"},"reference-count":19,"publisher":"Elsevier BV","issue":"1","license":[{"start":{"date-parts":[[2023,1,1]],"date-time":"2023-01-01T00:00:00Z","timestamp":1672531200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2023,1,1]],"date-time":"2023-01-01T00:00:00Z","timestamp":1672531200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"},{"start":{"date-parts":[[2022,10,5]],"date-time":"2022-10-05T00:00:00Z","timestamp":1664928000000},"content-version":"vor","delay-in-days":0,"URL":"http:\/\/creativecommons.org\/licenses\/by-nc-nd\/4.0\/"}],"content-domain":{"domain":["elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Hematology, Transfusion and Cell Therapy"],"published-print":{"date-parts":[[2023,1]]},"DOI":"10.1016\/j.htct.2022.09.1275","type":"journal-article","created":{"date-parts":[[2022,10,17]],"date-time":"2022-10-17T10:54:14Z","timestamp":1666004054000},"page":"83-89","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":5,"title":["Safety and efficacy of romiplostim in children and adolescents with Immune thrombocytopenia: A systematic review"],"prefix":"10.1016","volume":"45","author":[{"ORCID":"https:\/\/orcid.org\/0000-0001-8776-6057","authenticated-orcid":false,"given":"Fernanda Lubiana","family":"de Oliveira","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Fernanda Silva","family":"Sequeira","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Marlene Pereira","family":"Garanito","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"issue":"11","key":"10.1016\/j.htct.2022.09.1275_bib0001","doi-asserted-by":"crossref","first-page":"2386","DOI":"10.1182\/blood-2008-07-162503","article-title":"Standardization of terminology, definitions and outcome criteria in immune thrombocytopenic purpura of adults and children: report from an international working group","volume":"113","author":"Rodeghiero","year":"2009","journal-title":"Blood"},{"issue":"16","key":"10.1016\/j.htct.2022.09.1275_bib0002","doi-asserted-by":"crossref","first-page":"4190","DOI":"10.1182\/blood-2010-08-302984","article-title":"The American Society of Hematology 2011 evidence-based practice guideline for immune thrombocytopenia","volume":"117","author":"Neunert","year":"2011","journal-title":"Blood"},{"issue":"1","key":"10.1016\/j.htct.2022.09.1275_bib0003","doi-asserted-by":"crossref","first-page":"88","DOI":"10.1084\/jem.154.1.88","article-title":"Human megakaryocytes. II. Expression of platelet proteins in early marrow megakaryocytes","volume":"154","author":"Rabellino","year":"1981","journal-title":"J Exp Med"},{"issue":"4","key":"10.1016\/j.htct.2022.09.1275_bib0004","doi-asserted-by":"crossref","first-page":"589","DOI":"10.1111\/j.1365-2141.1984.tb02184.x","article-title":"Immunological study of in vitro maturation of human megakaryocytes","volume":"56","author":"Vinci","year":"1984","journal-title":"Br J Haematol"},{"issue":"3","key":"10.1016\/j.htct.2022.09.1275_bib0005","doi-asserted-by":"crossref","first-page":"887","DOI":"10.1182\/blood-2002-05-1475","article-title":"Immune thrombocytopenic purpura (ITP) plasma and purified ITP monoclonal autoantibodies inhibit megakaryocytopoiesis in vitro","volume":"102","author":"Chang","year":"2003","journal-title":"Blood"},{"issue":"23","key":"10.1016\/j.htct.2022.09.1275_bib0006","doi-asserted-by":"crossref","first-page":"2460","DOI":"10.1001\/jama.1978.03280500056020","article-title":"Antibody against megakaryocytes in idiopathic thrombocytopenic purpura","volume":"239","author":"McMillan","year":"1978","journal-title":"JAMA"},{"issue":"6","key":"10.1016\/j.htct.2022.09.1275_bib0007","doi-asserted-by":"crossref","first-page":"358","DOI":"10.3949\/ccjm.78gr.10005","article-title":"Immune thrombocytopenia: no longer \u2018idiopathic\u2019","volume":"78","author":"McCRAE","year":"2011","journal-title":"Cleve Clin J Med"},{"issue":"4","key":"10.1016\/j.htct.2022.09.1275_bib0008","doi-asserted-by":"crossref","first-page":"264","DOI":"10.3109\/09537104.2011.619601","article-title":"Romiplostim therapy in children with unresponsive chronic immune thrombocytopenia","volume":"23","author":"Mokhtar","year":"2012","journal-title":"Platelets"},{"key":"10.1016\/j.htct.2022.09.1275_bib0009","unstructured":"United States Food and Drug Administration approve romiplostim for pediatric patients with immune thrombocytopenia.https:\/\/www.fda.gov\/drugs\/fda-approves-romiplostim-pediatric-patients-immune-thrombocytopenia. Accessed December 13, 2021."},{"key":"10.1016\/j.htct.2022.09.1275_bib0010","unstructured":"National Cancer Institute. Common Terminology Criteria for Adverse Events v3.0 (CTCAE).https:\/\/ctep.cancer.gov\/protocoldevelopment\/electronic_applications\/docs\/ctcaev3.pdf. Accessed November 22, 2021."},{"issue":"1","key":"10.1016\/j.htct.2022.09.1275_bib0011","doi-asserted-by":"crossref","first-page":"28","DOI":"10.1182\/blood-2010-10-313908","article-title":"A randomized, double-blind study of romiplostim to determine its safety and efficacy in children with immune thrombocytopenia","volume":"118","author":"Bussel","year":"2011","journal-title":"Blood"},{"issue":"10039","key":"10.1016\/j.htct.2022.09.1275_bib0012","doi-asserted-by":"crossref","first-page":"45","DOI":"10.1016\/S0140-6736(16)00279-8","article-title":"Romiplostim in children with immune thrombocytopenia: a phase 3, randomised, double-blind, placebo-controlled study","volume":"388","author":"Tarantino","year":"2016","journal-title":"Lancet"},{"issue":"11","key":"10.1016\/j.htct.2022.09.1275_bib0013","doi-asserted-by":"crossref","first-page":"1172","DOI":"10.1182\/blood-2017-09-742353","article-title":"Splenectomy for immune thrombocytopenia: down but not out","volume":"131","author":"Chaturvedi","year":"2018","journal-title":"Blood"},{"issue":"23","key":"10.1016\/j.htct.2022.09.1275_bib0014","doi-asserted-by":"crossref","first-page":"3829","DOI":"10.1182\/bloodadvances.2019000966","article-title":"American Society of Hematology 2019 guidelines for immune thrombocytopenia","volume":"3","author":"Neunert","year":"2019","journal-title":"Blood Adv"},{"key":"10.1016\/j.htct.2022.09.1275_bib0015","unstructured":"United States Food and Drug Administration approve Promacta (Eltrombopag) Tablets for pediatric patients with immune thrombocytopenia.https:\/\/www.accessdata.fda.gov\/drugsatfda_docs\/nda\/2008\/022291s000_TOC.cfm. Accessed January 6, 2022."},{"issue":"15","key":"10.1016\/j.htct.2022.09.1275_bib0016","doi-asserted-by":"crossref","first-page":"1543","DOI":"10.1080\/14656566.2017.1373091","article-title":"Thrombopoietin-receptor agonists for children with immune thrombocytopenia: a systematic review","volume":"18","author":"Zhang","year":"2017","journal-title":"Expert Opin Pharmacother"},{"issue":"11","key":"10.1016\/j.htct.2022.09.1275_bib0017","doi-asserted-by":"crossref","first-page":"e28630","DOI":"10.1002\/pbc.28630","article-title":"Romiplostim treatment for children with immune thrombocytopenia: Results of an integrated database of five clinical trials","volume":"67","author":"Tarantino","year":"2020","journal-title":"Pediatr Blood Cancer"},{"issue":"11","key":"10.1016\/j.htct.2022.09.1275_bib0018","doi-asserted-by":"crossref","first-page":"1341","DOI":"10.1007\/s00277-011-1172-9","article-title":"Romiplostim in children with chronic refractory ITP: randomized placebo controlled study","volume":"90","author":"Elalfy","year":"2011","journal-title":"Ann Hematol"},{"issue":"9610","key":"10.1016\/j.htct.2022.09.1275_bib0019","doi-asserted-by":"crossref","first-page":"395","DOI":"10.1016\/S0140-6736(08)60203-2","article-title":"Efficacy of romiplostim in patients with chronic immune thrombocytopenic purpura: a double-blind randomised controlled trial","volume":"371","author":"Kuter","year":"2008","journal-title":"Lancet"}],"container-title":["Hematology, Transfusion and Cell Therapy"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S2531137922014262?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S2531137922014262?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2025,11,11]],"date-time":"2025-11-11T13:36:32Z","timestamp":1762868192000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S2531137922014262"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2023,1]]},"references-count":19,"journal-issue":{"issue":"1","published-print":{"date-parts":[[2023,1]]}},"alternative-id":["S2531137922014262"],"URL":"https:\/\/doi.org\/10.1016\/j.htct.2022.09.1275","relation":{},"ISSN":["2531-1379"],"issn-type":[{"value":"2531-1379","type":"print"}],"subject":[],"published":{"date-parts":[[2023,1]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Safety and efficacy of romiplostim in children and adolescents with Immune thrombocytopenia: A systematic review","name":"articletitle","label":"Article Title"},{"value":"Hematology, Transfusion and Cell Therapy","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.htct.2022.09.1275","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2022 Associa\u00e7\u00e3o Brasileira de Hematologia, Hemoterapia e Terapia Celular. Published by Elsevier Espa\u00f1a, S.L.U.","name":"copyright","label":"Copyright"}]}}